Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.60 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755963 | 0.89 | DDB1 (0.57) | DDB1CRBNGBA1MAOBHDAC8 | |
| SCHEMBL2729166 | 0.88 | DDB1 (0.55) | DDB1CRBNGBA1MAOBPOLB | |
| Hydrochloric Acid SCHEMBL15650706 | 0.88 | DDB1 (0.55) | DDB1CRBNGBA1MAOBHDAC8 | |
| SCHEMBL1963328 | 0.82 | CRBN (0.41) | DDB1CRBNPOLBKMT2A | |
| SCHEMBL31300144 | 0.82 | DDB1 (0.41) | DDB1CRBNTACR2POLBCYP19A1 | |
| SCHEMBL3051430 | 0.82 | ALDH1A1 (0.44) | DDB1CRBNPOLBALDH1A1CTSD | |
| SCHEMBL28260107 | 0.82 | KMT2A (0.43) | DDB1CRBNPOLBALDH1A1RAB9A | |
| SCHEMBL6211599 | 0.82 | MAOB (0.46) | DDB1CRBNMAOB | |
| SCHEMBL27429818 | 0.82 | GSK3B (0.49) | DDB1CRBNALDH1A1CTSD | |
| SCHEMBL8070063 | 0.80 | DDB1 (0.42) | DDB1CRBNPOLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | claimed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| CN-106414534-B | It is suitable as the urea preparation of the stable storage of rheology control agent | 比克化学股份有限公司 | 2019-05-07 | — | — | CN | disclosed |
| EP-3131939-A1 | STORAGE-STABLE UREA PREPARATIONS WHICH ARE SUITABLE AS RHEOLOGY CONTROL AGENTS | BYK-Chemie GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| CN-106414534-A | Storage-stable urea preparations which are suitable as rheology control agents | 比克化学股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| WO-2015158794-A1 | STORAGE-STABLE UREA PREPARATIONS WHICH ARE SUITABLE AS RHEOLOGY CONTROL AGENTS | BYK-CHEMIE GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| CN-1440401-A | Amino substituted dibenzothiophene derivatives for treatmnt of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2003-09-03 | — | — | CN | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| WO-2003007940-A1 | LACTAM AND THIOLACTAM DERIVATIVES AS ANESTHETIC AND CONSCIOUS SEDATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997023202-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | DDB1 3351/4885CRBN 4761/4885GBA1 384/4885 |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | DDB1 1094/4885CRBN 189/4885GBA1 3683/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | DDB1 500/4885CRBN 3474/4885GBA1 85/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | DDB1 861/4885CRBN 3072/4885GBA1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.